Sunvozertinib

small molecule

Identifier: CI-DRUG-00000565
Entity page: /drug/sunvozertinib ↗
Edges: 68

Neighbours: 4 cancers15 variants10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Sunvozertinib predicts response to …PREDICTS_RESPONSE_TO15 of 48show all (up to 200)
← predicts response to	EGFR Exon 20 Insertioninsertion	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	EGFR C775_R776insNPHVCinsertion

Sunvozertinib investigated for …INVESTIGATED_FOR3 of 3
→ investigated for	Lung Non-Small Cell Carcinomasubtype 7 source records aggregated	supports	A	Lung Non-Small Cell Carcinoma	7	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	3	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Follicular Lymphomahematologic_malignancy	unknown	1	Follicular Lymphoma	1	Curated	chembl	graph →

Sunvozertinib investigated for …INVESTIGATED_FOR3 of 3

→ investigated for

Lung Non-Small Cell Carcinomasubtype

7 source records aggregated

supports

Lung Non-Small Cell Carcinoma

Curated

Sunvozertinib investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 12 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	B-Cell Non-Hodgkin Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →

Sunvozertinib studied in …STUDIED_INderived10 of 14show all (up to 200)
→ studied in	NCT05559645NA · recruiting Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07079475Phase 1/Phase 2 · recruiting Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05668988Phase 3 · active not recruiting A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06195189Phase 1/Phase 2 · recruiting Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 14 trials list this drug (13 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06905197Phase 1 · recruiting A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03974022Phase 1/Phase 2 · active not recruiting Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07117890Phase 2 · recruiting Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07182682Phase 3 · recruiting A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07274761Phase 2 · active not recruiting Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. · 14 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths